16,323 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Tema Etfs LLC

Tema Etfs LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 16,323 shares of the biopharmaceutical company's stock, valued at approximately $3,841,000. Alnylam Pharmaceuticals accounts for about 1.6% of Tema Etfs LLC's portfolio, making the stock its 24th biggest position.

A number of other hedge funds also recently bought and sold shares of the company. Siemens Fonds Invest GmbH lifted its holdings in shares of Alnylam Pharmaceuticals by 137.7% during the fourth quarter. Siemens Fonds Invest GmbH now owns 3,245 shares of the biopharmaceutical company's stock worth $764,000 after buying an additional 1,880 shares during the last quarter. Silvercrest Asset Management Group LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth $1,151,000. Quantinno Capital Management LP grew its position in Alnylam Pharmaceuticals by 35.4% in the 4th quarter. Quantinno Capital Management LP now owns 4,556 shares of the biopharmaceutical company's stock worth $1,072,000 after purchasing an additional 1,190 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in shares of Alnylam Pharmaceuticals by 51.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 38,672 shares of the biopharmaceutical company's stock worth $9,100,000 after purchasing an additional 13,187 shares during the period. Finally, Nissay Asset Management Corp Japan ADV raised its position in shares of Alnylam Pharmaceuticals by 2.1% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 15,947 shares of the biopharmaceutical company's stock valued at $3,795,000 after buying an additional 324 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 1.0%

Shares of ALNY stock traded down $2.96 on Friday, reaching $286.04. 219,371 shares of the stock were exchanged, compared to its average volume of 882,629. The stock has a 50 day moving average price of $257.45 and a 200 day moving average price of $254.27. The stock has a market cap of $37.30 billion, a PE ratio of -131.82 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a one year low of $146.79 and a one year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. The company's revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ALNY. Scotiabank boosted their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price for the company. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Royal Bank of Canada increased their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. Finally, William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.